Selective cathepsin s inhibition with MIV-247 attenuates mechanical allodynia and enhances the antiallodynic effects of gabapentin and pregabalin in a mouse model of neuropathic pain

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 3, 2016, Pages 387-396

  Hewitt, Ellen ^a   Pitcher, Thomas ^b   Rizoska, Biljana ^a   Tunblad, Karin ^a   Henderson, Ian ^a   Sahlberg, Britt Louise ^a   Grabowska, Urszula ^a   Classon, Björn ^a   Edenius, Charlotte ^a   Malcangio, Marzia ^b   Lindström, Erik ^a  

^a MEDIVIR AB   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; GABAPENTIN; MIV 247; PREGABALIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; AMINE; CATHEPSIN; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DIPEPTIDE; MIV-247; PROTEINASE INHIBITOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIALLODYNIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG STRUCTURE; EFFECTIVE DOSE (PHARMACOLOGY); ENZYME INHIBITION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VON FREY TEST; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; HUMAN; HYPERALGESIA; NEURALGIA;

AMINES; ANIMALS; BEHAVIOR, ANIMAL; CATHEPSINS; CYCLOHEXANECARBOXYLIC ACIDS; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPERALGESIA; MALE; MICE; NEURALGIA; PREGABALIN; PROTEASE INHIBITORS;

EID: 84983731357     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.232926     Document Type: Article

References (35)

1. Alier KA, Endicott JA, Stemkowski PL, Cenac N, Cellars L, Chapman K, Andrade- Gordon P, Vergnolle N, and Smith PA (2008) Intrathecal administration of proteinase- Activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther 324:224-233.
2. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, and Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 280:1831-1836.
3. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, and Bockbrader HN (2005) Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46: 1407-1413.
4. Cattaruzza F, Lyo V, Jones E, Pham D, Hawkins J, Kirkwood K, Valdez-Morales E, Ibeakanma C, Vanner SJ, and Bogyo M, et al. (2011) Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology 141:1864-1874.e1-3.
5. Chang CY, Challa CK, Shah J, and Eloy JD (2014) Gabapentin in acute postoperative pain management. BioMed Res Int 2014:631756.
6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
7. Clark AK and Malcangio M (2012) Microglial signalling mechanisms: cathepsin S and fractalkine. Exp Neurol 234:283-292.
8. Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M, Wotherspoon G, Winter J, and Ullah J, et al. (2007) Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 104: 10655-10660.
9. Clark AK, Yip PK, and Malcangio M (2009) The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci 29:6945-6954.
10. Clark AK, Wodarski R, Guida F, Sasso O, and Malcangio M (2010) Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia 58:1710-1726.
11. Coyle DE (1998) Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 23:75-83.
12. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462.
13. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, and Levy RM, et al. (2010) Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 85(3 Suppl)S3-S14.
14. Elmariah SB, Reddy VB, and Lerner EA (2014) Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist. PLoS One 9:e99702.
15. Fehrenbacher JC, Taylor CP, and Vasko MR (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105:133-141.
16. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, and Göthert M (2002) Inhibition of neuronal Ca(21) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42:229-236.
17. Gore M, Sadosky A, Tai KS, and Stacey B (2007) A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther 29:1655-1670.
18. Hathway GJ, Vega-Avelaira D, Moss A, Ingram R, and Fitzgerald M (2009) Brief, low frequency stimulation of rat peripheral C-fibres evokes prolonged microglialinduced central sensitization in adults but not in neonates. Pain 144:110-118.
19. Huang Z, Tao K, Zhu H, Miao X, Wang Z, Yu W, and Lu Z (2011) Acute PAR2 activation reduces GABAergic inhibition in the spinal dorsal horn. Brain Res 1425:20-26.
20. Irie O, Kosaka T, Ehara T, Yokokawa F, Kanazawa T, Hirao H, Iwasaki A, Sakaki J, Teno N, and Hitomi Y, et al. (2008) Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. J Med Chem 51:5502-5505.
21. Lana B, Schlick B, Martin S, Pratt WS, Page KM, Goncalves L, Rahman W, Dickenson AH, Bauer CS, and Dolphin AC (2014) Differential upregulation in DRG neurons of an a2d-1 splice variant with a lower affinity for gabapentin after peripheral sensory nerve injury. Pain 155:522-533.
22. Malmberg AB and Basbaum AI (1998) Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76: 215-222.
23. McMahon SB and Malcangio M (2009) Current challenges in glia-pain biology. Neuron 64:46-54.
24. Moore RA, Wiffen PJ, Derry S, and McQuay HJ (2011) Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev (3): CD007938.
25. Raffa RB, Pergolizzi JV Jr, and Tallarida RJ (2010) The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain 11:701-709.
26. Reddy VB, Shimada SG, Sikand P, Lamotte RH, and Lerner EA (2010) Cathepsin S elicits itch and signals via protease- Activated receptors. J Invest Dermatol 130:1468-1470.
27. Seltzer Z, Dubner R, and Shir Y (1990) A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43:205-218.
28. Stacey BR and Glanzman RL (2003) Use of gabapentin for postherpetic neuralgia: Results of two randomized, placebo-controlled studies. Clin Ther 25:2597-2608.
29. Staniland AA, Clark AK, Wodarski R, Sasso O, Maione F, D'Acquisto F, and Malcangio M (2010) Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 114:1143-1157.
30. Stanley JL, Lincoln RJ, Brown TA, McDonald LM, Dawson GR, and Reynolds DS (2005) The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol 19:221-227.
31. Suter MR, Berta T, Gao YJ, Decosterd I, and Ji RR (2009) Large A-fiber activity is required for microglial proliferation and p38 MAPK activation in the spinal cord: different effects of resiniferatoxin and bupivacaine on spinal microglial changes after spared nerve injury. Mol Pain 5:53.
32. Sutton KG, Martin DJ, Pinnock RD, Lee K, and Scott RH (2002) Gabapentin inhibits high- Threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 135:257-265.
33. Takasusuki T and Yaksh TL (2011) The effects of intrathecal and systemic gabapentin on spinal substance P release. Anesth Analg 112:971-976.
34. Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319:1-7.
35. Zhao P, Lieu T, Barlow N, Metcalf M, Veldhuis NA, Jensen DD, Kocan M, Sostegni S, Haerteis S, and Baraznenok V, et al. (2014) Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. J Biol Chem 289:27215-27234.